Podium to Practice: Chicago 2025 – Lung: HERTHENA-Lung02
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
8506 – Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.
This program has been made possible through unrestricted support from Boehringer Ingelheim.
Studies/trials discussed:
8506 – Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.